Table 1.
Mean Hospital Readmissions, Admissions with ICU, and Length of Stay
| Chemotherapy regimen | Mean admissions per line of therapy, N | Mean length of stay, days | Mean percent of total admissions | ||
|---|---|---|---|---|---|
| With readmissions, % | With ICU use, % | With surgery, % | |||
| Commercial analysis (MarketScan 2014–2018), N = 3904 | |||||
| First-line FOLFIRINOX | 0.70 | 5.96 | 23 | 21 | 16 |
| First-line gemcitabine/nab-paclitaxel | 0.78 | 6.01 | 24 | 22 | 13 |
| First-line gemcitabine monotherapy | 0.54 | 6.88 | 22 | 25 | 14 |
| Second-/third-line liposomal irinotecan | 0.60 | 6.90 | 17 | 21 | 5 |
| Medicare analysis (Medicare 100% research identifiable data 2014–2017), N = 16,065 | |||||
| First-line FOLFIRINOX | 0.85 | 6.79 | 16 | 23 | 17 |
| First-line gemcitabine/nab-paclitaxel | 0.95 | 6.62 | 21 | 25 | 11 |
| First-line gemcitabine monotherapy | 0.75 | 7.00 | 20 | 26 | 12 |
| Second-/third-line liposomal irinotecan | 0.61 | 6.79 | 17 | 21 | 8 |
FOLFIRINOX indicates 5-fluorouracil, leucovorin, oxaliplatin, and irinotecan; ICU, intensive care unit.